Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Drug

Livzon Pharmaceutical Gets CDE Green Light for JP-1366 Reflux Esophagitis Clinical Study

Fineline Cube Feb 23, 2024

Livzon Pharmaceutical Group Inc. (HKG: 1513), a leading Chinese pharmaceutical company, has announced that its...

Company Drug

Hinova Pharmaceuticals’ HP537 Receives CDE Approval for Clinical Study in Hematologic Malignancies

Fineline Cube Feb 23, 2024

Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech company based in Chengdu, has announced that it...

Company Drug

Jiangsu Hengrui’s CD79b Targeting ADC SHR-A1912 Earns FDA Fast-Track Designation for R/R DLBCL

Fineline Cube Feb 23, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has announced that...

Company Medical Device

Rossum Robot’s Intelligent Surgical Robot for Trauma and Spinal Surgery Clears NMPA Approval

Fineline Cube Feb 23, 2024

Rossum Robot, a Beijing-based developer of orthopedic surgical robots specializing in pelvic fracture procedures, has...

Company Drug

AstraZeneca’s Tagrisso Meets PFS Endpoint in Late-Stage NSCLC Trial and Expands FDA Approval

Fineline Cube Feb 23, 2024

AstraZeneca (AZ; NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced that a late-stage trial...

Company Drug

Pfizer’s Velsipity Approved by European Commission for Moderately to Severely Active Ulcerative Colitis

Fineline Cube Feb 22, 2024

The European Commission (EC) has granted regulatory approval to Pfizer (NYSE: PFE) for its S1P...

Company Drug

FDA Authorizes Biweekly Dosing for J&J’s Tecvayli in Multiple Myeloma Treatment

Fineline Cube Feb 22, 2024

The US Food and Drug Administration (FDA) has granted authorization for a biweekly dosing regimen...

Company

AbbVie CEO Rick González to Retire, Succeeded by Robert A. Michael

Fineline Cube Feb 22, 2024

AbbVie (NYSE: ABBV), a leading US pharmaceutical company, has announced that Rick González, who has...

Company Deals

Sinopharm Plans to Privatize China Traditional Medicine Holdings in a USD 2 Billion Deal

Fineline Cube Feb 22, 2024

China Traditional Medicine Holdings (HKG: 0570; China TCM) has announced that its controlling shareholder, the...

Company Drug

Immune-Onc Therapeutics’ IO-202 Earns Orphan Drug Designation for CMML from US FDA

Fineline Cube Feb 22, 2024

Immune-Onc Therapeutics, the Hangzhou-based subsidiary of US company Immune-Onc Therapeutics Inc., has announced that it...

Company Drug

Innovent Biologics’ Tyvyt Receives Marketing Approval for Multiple Indications in Macau

Fineline Cube Feb 22, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company Medical Device

Zylox-Tonbridge Receives UAE Approval for Five Medical Devices, Expands Middle East Presence

Fineline Cube Feb 22, 2024

Zylox-Tonbridge (HKG: 2190), a Chinese specialist in medical devices, has announced a series of product...

Company Drug

MSD’s Belzutifan and Sperogenix’s Vamorolone Targeted for Priority Review by China’s CDE

Fineline Cube Feb 22, 2024

The Center for Drug Evaluation (CDE) website has indicated that Merck, Sharp & Dohme’s (MSD;...

Policy / Regulatory

CDE Opens Consultation on 79th Batch of Generic Drug Reference Preparations

Fineline Cube Feb 22, 2024

The Center for Drug Evaluation (CDE) has issued a call for feedback on the 79th...

Company Drug

Zhongsheng Pharmaceutical Initiates Phase II Trials for Polypeptide Drug RAY1225 in Diabetes and Obesity

Fineline Cube Feb 22, 2024

Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317), a Chinese pharmaceutical company, has announced the initiation...

Company Deals

AstraZeneca Secures Shareholder Approval for $1 Billion Acquisition of Gracell Biotechnologies

Fineline Cube Feb 21, 2024

The proposed acquisition of China-based Gracell Biotechnologies Inc. (Nasdaq: GRCL) by UK pharmaceuticals giant AstraZeneca...

Policy / Regulatory

FDA Issues Warning Letter to Sichuan Deebio for cGMP Violations in API Manufacturing

Fineline Cube Feb 21, 2024

The U.S. Food and Drug Administration (FDA) has issued a warning letter to Sichuan Deebio...

Company Drug

Bayer Advances BAY3018250 into Phase II Trial Following Successful Phase I Completion

Fineline Cube Feb 21, 2024

Germany’s Bayer (ETR: BAYN) has launched a double-blind, placebo-controlled mid-stage trial for its potential first-in-class...

Company Drug

BMS Seeks FDA Priority Review for Krazati in Advanced Colorectal Cancer

Fineline Cube Feb 21, 2024

Bristol Myers Squibb (BMS; NYSE: BMY) has submitted a priority review application to the U.S....

Company Drug

WuXi ATU’s Philadelphia Facility Approved for Amtagvi Production Following FDA Nod

Fineline Cube Feb 21, 2024

WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec (SHA: 603259, HKG:...

Posts pagination

1 … 399 400 401 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.